Alba Font Tello
About Alba Font Tello
Alba Font Tello is a Principal Scientist at Bristol Myers Squibb in Cambridge, Massachusetts, specializing in cancer immunotherapy.
Title and Current Role
Alba Font Tello currently holds the position of Principal Scientist at Bristol Myers Squibb, located in Cambridge, Massachusetts, United States. In this role, she collaborates with cross-functional teams to develop novel therapeutic strategies and has made significant contributions to the field of cancer immunotherapy.
Past Positions at Dana-Farber Cancer Institute
Alba Font Tello has an extensive history at Dana-Farber Cancer Institute, having served in various capacities. She first joined as a Research Scholar in 2015 for a period of five months. Subsequently, she was promoted to Research Associate, a role she held from 2016 to 2018. During her tenure from 2018 to 2020, she advanced to the position of Staff Scientist. Throughout her time at Dana-Farber, she published multiple research papers in peer-reviewed journals.
Academic Background
Alba Font Tello has a robust academic background, having completed her education at Universitat Pompeu Fabra. She earned her Bachelor's degree in Human Biology from 2008 to 2012. Following this, she obtained a Master of Science (M.S) in Clinical Laboratory from 2012 to 2013. She then pursued a Doctor of Philosophy (PhD) in Biomedical Research, which she completed from 2013 to 2018.
Early Research Experience
Alba Font Tello's early research career included several roles at Hospital del Mar- Parc de Salut MAR and Universitat Pompeu Fabra. She was an Undergraduate Student Researcher in 2012 for four months and a Master Student from 2012 to 2013 for ten months. From 2013 to 2018, she was a PhD Candidate at Universitat Pompeu Fabra and Hospital del Mar- Parc de Salut MAR, based at the Barcelona Biomedical Research Park.
Contributions to Cancer Immunotherapy
Specializing in cancer immunotherapy, Alba Font Tello has contributed to significant advancements in this field. She has presented her research findings at prominent international conferences such as the American Association for Cancer Research (AACR) Annual Meeting. At Bristol Myers Squibb, she continues to innovate in therapeutic development while mentoring junior scientists and fostering a collaborative research environment.